HSBC upgraded Moderna (MRNA) to Hold from Reduce with a $58 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna (MRNA) and Other Vaccine Stocks Fall on News of RFK Jr. Health Nomination
- Cantor sees six changes to Nasdaq 100 Index in December rebalance
- Deutsche downgrades GSK to Hold on Trump’s RFK nomination
- VOO ETF Update, 11/15/2024
- Wolfe Research starts Moderna at Underperform, sees limited upside opportunity